Last updated: 2026-09-05 00:39:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
OmniAb, Inc. (OABI) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $4,33, with a market capitalization of $732,77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,30 to $5,43. This page covers its latest market performance, valuation, price trends and company information.
$732,77M | |
$4,78 | |
$6,72 | |
$1,22 | |
$4,75 | |
1,53M | |
-- | |
-- | |
$5,43 | |
$1,30 | |
-- | |
-- |
OmniAb, Inc. (OABI) last closed at $4,75 as of 2026-09-04 23:31:00, unchanged from the previous close of $4,75.
During the latest regular trading session, OABI traded between $1,22 and $6,72, with a volume of 1,53M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, OmniAb, Inc. (OABI) moved from $4,44 to $4,33, representing a decline of 2,59% ($0,12).
The stock traded between $4,28 and $4,94 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1,96 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 73,2%
OABI is currently trading at $4,33, placing it 73,2% of the way from its 52-week low of $1,30 to its 52-week high of $5,43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 89 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OmniAb, Inc. (OABI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.